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Introduction
Enthesitis Related Arthritis (ERA) is a sub-type of JIA
with emerging phenotypic differences. Clinical onset is
often insidious and there is evidence to suggest long-
term remission is less common. There is limited data
comparing the treatment of ERA to other sub-types for
the adolescent age spectrum.
Objectives
To determine if DMARD and biologic use differed in
patients with ERA compared to other sub-types of JIA
during adolescence.
Methods
A detailed retrospective review of medical notes and
referral documentation for all JIA patients (N = 159)
attending an Adolescent Rheumatology Centre over a
three month period was made.
Results
The median age overall was 17.1(13-21) years. 28.9%
(46) of individuals had ERA, of which 69.6% (39) were
male. Mean duration of disease since diagnosis was 7.3
years (SD=+/-4.9). Of the other JIA subtypes; 21.4%
(34), 17.6% (28) and 11.9% (19) had Extended Oligoarti-
cular Arthritis (EOA), Polyarticular Rheumatoid Factor
Positive (JIA RF+) and Polyarticular Rheumatoid Factor
Negative (JIA RF-) JIA, respectively. There was no
significant difference in mean time since diagnosis
between ERA and the other JIA subgroups.
The time between diagnosis and commencing a
DMARD, primarily Methotrexate, was significantly
longer in the ERA group (31.6 vs. 22.5 months, p =
0.008). Mean duration on Methotrexate was significantly
shorter in ERA compared to EOA and JIA RF+ sub-
groups (31 vs. 47 and 49 months respectively, p = 0.03).
80.4% of ERA patients had been started on Methotrex-
ate since diagnosis, with 63% continuing it at the time
of the study. 57.14% of those that had stopped were dis-
continued due to poor treatment response. This was
substantially higher than EOA and JIA RF- (36.6% and
25% respectively). 17% of ERA patients had had Sulfasa-
lazine treatment in the past compared to 5.7% and 5.8%
of Polyarticular RF (polya) and EOA, respectively. The
duration of Sulfasalazine treatment was significantly
longer when compared with polya and EOA (36 months
vs. 23 and 5 months, respectively, p = 0.034).
At the time of study, a greater proportion of ERA
patients were on biological treatment when compared
with polya and EOA (38.9% vs. 30.7% and 17.6%, respec-
tively, p < 0.001). 10.8% of ERA were using Infliximab
compared with 0% of EOA and 1.9% of polya (p < 0.001).
Adalimumab use was more prevalent amongst ERA com-
pared with EOA and polya (13% vs. 0% and 3.8%, respec-
tively, (p = 0.008). The time from starting a DMARD to
starting a biologic was significantly shorter in ERA com-
pared to EOA (32.8 vs. 72.4 months, p = 0.038).
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Conclusion
In this cohort, adolescent patients with ERA were
started on Methotrexate later and discontinued earlier
than other groups. There was also comparatively greater
use of Sulfasalazine in ERA patients.
At the time of this study, use of biological agents,
especially Infliximab and Adalimumab was significantly
higher in ERA. Furthermore, ERA patients were started
on biological therapy earlier, once DMARD treatment
had commenced; suggesting that escalation of treatment
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